Skip to main content

Table 7 Total treatment costs for with and without SEB scenarios in year 4

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Patient type (CKD stage) Treatments for anemia Year 4 Total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 38,308,544 25,996,178
Long acting ESA (SC) 39,849,400 27,041,803
Epoetin SEB - 13,411,903
Stage V Short acting ESA (SC) 29,148,598 19,780,239
Long acting ESA (SC) 20,185,070 13,697,588
Short acting ESA (IV) 119,750,354 81,262,590
Long acting ESA (IV) 83,272,569 56,508,765
Epoetin SEB - 43,304,392
Total 330,514,535 281,003,457
  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.
Back to article page

Canadian Journal of Kidney Health and Disease

ISSN: 2054-3581

Contact us